NT5E and ovarian cancer: In human cancers, such as triple negative breast cancer (TNBC) and ovarian cancer, CD73 expression is generally associated with poor clinical outcomes, impaired tumor immune surveillance and resistance to chemotherapy (Loi et al., 2013; Bareche et al., 2021).